SHIFT PHARMACEUTICALS
Shift Pharmaceuticals provides research and development of Antisense Oligonucleotides as a medicine for a variety of genetic disorders.
SHIFT PHARMACEUTICALS
Industry:
Pharmaceutical Product Research Professional Services
Founded:
2017-01-01
Address:
Overland Park, Kansas, United States
Country:
United States
Website Url:
http://www.shiftpharmaceuticals.com
Total Employee:
1+
Status:
Active
Contact:
+1 6268932514
Official Site Inspections
http://www.shiftpharmaceuticals.com Semrush global rank: 5.46 M Semrush visits lastest month: 1.56 K
- Host name: biz252.inmotionhosting.com
- IP address: 192.249.121.28
- Location: Los Angeles United States
- Latitude: 33.956
- Longitude: -118.3887
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90045
More informations about "Shift Pharmaceuticals"
About Shift | Shift Pharmaceuticals
Chris Lorson, Ph.D. – Chief Scientific Officer. Dr. Lorson is a world leader in the research space of spinal muscular atrophy, publishing extensively in the field for over 20 years.See details»
Shift Pharmaceuticals - Crunchbase Company Profile & Funding
Shift Pharmaceuticals provides research and development of Antisense Oligonucleotides as a medicine for a variety of genetic disorders.See details»
Shift Pharmaceuticals Company Profile | Management and
Www.shiftpharmaceuticals.com Shift Pharmaceuticals Profile and History Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a …See details»
Shift Pharmaceuticals Holdings, Inc · 1601 S Providence Rd, …
SHIFT PHARMACEUTICALS HOLDINGS, INC is an entity in Columbia, Missouri registered with the System for Award Management (SAM) of U.S. General Services Administration (GSA). …See details»
Shift Pharmaceuticals - LinkedIn
Shift Pharmaceuticals is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders, including Charcot Marie Tooth Syndrome (CMT1A) and Spinal Muscular Atrophy (SMA).See details»
Shift Pharmaceuticals LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Shift Pharmaceuticals LLC of Columbia, MO. Get the latest business insights from Dun & Bradstreet.See details»
Shift Pharmaceuticals - PitchBook
Shift Pharmaceuticals General Information Description. Developer of a genetic disorder technology designed to analyze a novel series of morpholino-based antisense oligonucleotide …See details»
Shift Pharmaceuticals - Products, Competitors, Financials, …
Shiftpharmaceuticals.com. Overview & Products; People; Founded Year 2017. About Shift Pharmaceuticals. Shift Pharmaceuticals focuses on developing targeted therapeutics in the …See details»
Shift Pharmaceuticals - Overview, News & Similar companies
View Shift Pharmaceuticals (www.shiftpharmaceuticals.com) location in Missouri, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Shift Pharmaceuticals Holdings, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Shift Pharmaceuticals Holdings, Inc. of Overland Park, KS. Get the latest business insights from …See details»
Shift Pharmaceuticals Holdings Inc - Cortera
Free Business profile for SHIFT PHARMACEUTICALS HOLDINGS INC at 1601 S Providence Rd, Columbia, MO, 65203-3598, US. SHIFT PHARMACEUTICALS HOLDINGS INC specializes in: …See details»
Shift Pharmaceuticals Holdings, Inc. in Overland Park, KS - (626) …
Shift Pharmaceuticals Holdings, Inc. (trade name Shift Pharmaceuticals) is in the Medicinals and Botanicals business. View competitors, revenue, employees, website and phone number.See details»
Shift Pharmaceuticals - Phone, Email, Employees, CEO, VP, 2024
Headquarters: Overland Park, Kansas, Us , Overland Park, Kansas, United States MoreSee details»
Shift News | Shift Pharmaceuticals
Press Releases. 2024. May 2024 – Shift Pharmaceuticals Selected to Present at 2024 Peripheral Nerve Society Annual Meeting Apr 2024 – Shift Pharmaceuticals Engages OGAdvisors for …See details»
Shift Pharmaceuticals Awarded $3 Million for Spinal Muscular …
The core platform targeting SMA has been validated by our academic partners at The University of Missouri and a patent has been filed on the intellectual property, which is in the process of …See details»
Shift Pharmaceuticals Holdings, Inc. | SBIR.gov
Abstract: The objective of this project is to develop a safe, effective antisense oligonucleotide with Phosphorodiamidate Morpholino Oligomer (PMO) backbone chemistry capable of significantly …See details»
Shift’s Technology - Shift Pharmaceuticals
Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders.See details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different …See details»
Shift’s Pipeline - Shift Pharmaceuticals
Shift’s Pipeline Spinal Muscular Atrophy. 50,000 SMA patients in US/EU/Japan; Leading genetic cause of infantile death; Severe symptoms are lifelong for survivorsSee details»
Shift Pharmaceuticals, CMTA Partner
Nov 3, 2022 www.shiftpharmaceuticals.com . CONTACT: Shift Pharmaceuticals Dr. Steve O’Connor, CEO (626) 893-2514 [email protected]. Title: Shift CMTA …See details»